{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=ISL", "query": { "intervention": "ISL" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 28, "total_pages": 3, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=ISL&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-03T08:12:08.737Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04564547", "title": "Dose Ranging, Switch Study of Islatravir (MK-8591) and Ulonivirine (MK-8507) Once-Weekly in Virologically-Suppressed Adults With Human Immunodeficiency Virus Type 1 (HIV-1) [MK-8591-013]", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "HIV-1 Infection" ], "interventions": [ { "name": "Islatravir", "type": "DRUG" }, { "name": "Ulonivirine", "type": "DRUG" }, { "name": "BIC/FTC/TAF", "type": "DRUG" }, { "name": "Placebo to ISL", "type": "DRUG" }, { "name": "Placebo to Ulonivirine", "type": "DRUG" }, { "name": "Placebo to BIC/FTC/TAF", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 161, "start_date": "2021-03-09", "completion_date": "2025-01-30", "has_results": true, "last_update_posted_date": "2026-01-26", "last_synced_at": "2026-09-03T08:12:08.737Z", "location_count": 10, "location_summary": "Phoenix, Arizona • Los Angeles, California • Ft. Pierce, Florida + 7 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Ft. Pierce", "state": "Florida" }, { "city": "West Palm Beach", "state": "Florida" }, { "city": "Decatur", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT04564547" }, { "nct_id": "NCT04568603", "title": "Islatravir and Methadone Pharmacokinetics (MK-8591-029)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HIV-1 Infection" ], "interventions": [ { "name": "Islatravir", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 14, "start_date": "2020-10-16", "completion_date": "2021-07-09", "has_results": true, "last_update_posted_date": "2025-01-28", "last_synced_at": "2026-09-03T08:12:08.737Z", "location_count": 2, "location_summary": "Hollywood, Florida • Salt Lake City, Utah", "locations": [ { "city": "Hollywood", "state": "Florida" }, { "city": "Salt Lake City", "state": "Utah" } ], "official_url": "https://clinicaltrials.gov/study/NCT04568603" }, { "nct_id": "NCT04295772", "title": "Doravirine/Islatravir (DOR/ISL) in Pediatric Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Who Are <18 Years of Age and Weigh ≥35 kg (MK-8591A-028)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "HIV-1 Infection" ], "interventions": [ { "name": "DOR/ISL", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "17 Years", "sex": "ALL", "summary": "Up to 17 Years" }, "enrollment_count": 42, "start_date": "2020-11-26", "completion_date": "2023-01-25", "has_results": true, "last_update_posted_date": "2024-01-31", "last_synced_at": "2026-09-03T08:12:08.737Z", "location_count": 4, "location_summary": "Washington D.C., District of Columbia • Atlanta, Georgia • Baltimore, Maryland + 1 more", "locations": [ { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT04295772" }, { "nct_id": "NCT05705349", "title": "DOR/ISL in HIV-1 Antiretroviral Treatment-naïve Participants (MK-8591A-053)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "HIV-1 Infection" ], "interventions": [ { "name": "DOR/ISL", "type": "DRUG" }, { "name": "BIC/FTC/TAF", "type": "DRUG" }, { "name": "Placebo to DOR/ISL", "type": "DRUG" }, { "name": "Placebo to BIC/FTC/TAF", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 537, "start_date": "2023-03-08", "completion_date": "2029-08-05", "has_results": false, "last_update_posted_date": "2025-10-23", "last_synced_at": "2026-09-03T08:12:08.737Z", "location_count": 38, "location_summary": "Phoenix, Arizona • Beverly Hills, California • Los Angeles, California + 29 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT05705349" }, { "nct_id": "NCT06891066", "title": "A Study of Islatravir (ISL) and Ulonivirine (ULO) Once Weekly (QW) in Virologically Suppressed Adults With Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8591B-060)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Human Immunodeficiency Virus Type 1 (HIV-1) Infection" ], "interventions": [ { "name": "ISL", "type": "DRUG" }, { "name": "ULO", "type": "DRUG" }, { "name": "BIC/FTC/TAF", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 150, "start_date": "2025-04-14", "completion_date": "2031-09-30", "has_results": false, "last_update_posted_date": "2025-10-16", "last_synced_at": "2026-09-03T08:12:08.737Z", "location_count": 11, "location_summary": "San Francisco, California • West Hollywood, California • Washington D.C., District of Columbia + 8 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "West Hollywood", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Orlando", "state": "Florida" }, { "city": "West Palm Beach", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT06891066" }, { "nct_id": "NCT06811246", "title": "A Clinical Study of Islatravir and Its Interaction With Lamivudine (MK-8591-058)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy" ], "interventions": [ { "name": "Islatravir (ISL)", "type": "DRUG" }, { "name": "Lamivudine (3TC)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 20, "start_date": "2024-02-07", "completion_date": "2024-07-14", "has_results": false, "last_update_posted_date": "2025-02-06", "last_synced_at": "2026-09-03T08:12:08.737Z", "location_count": 1, "location_summary": "Lincoln, Nebraska", "locations": [ { "city": "Lincoln", "state": "Nebraska" } ], "official_url": "https://clinicaltrials.gov/study/NCT06811246" }, { "nct_id": "NCT04248907", "title": "Transtibial Pin Lock Suspension at Varying Distraction Values Using a Modified Air Bladder Casting System", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Amputation" ], "interventions": [ { "name": "0 pound tension", "type": "OTHER" }, { "name": "2 pound tension", "type": "OTHER" }, { "name": "4 pound tension", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Loma Linda University", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2020-01-28", "completion_date": "2020-04-27", "has_results": false, "last_update_posted_date": "2020-05-01", "last_synced_at": "2026-09-03T08:12:08.737Z", "location_count": 1, "location_summary": "Loma Linda, California", "locations": [ { "city": "Loma Linda", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04248907" }, { "nct_id": "NCT04233879", "title": "Study of Doravirine/Islatravir (DOR/ISL 100 mg/0.75 mg) to Evaluate the Antiretroviral Activity, Safety, and Tolerability in Treatment-Naïve Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Infection (MK-8591A-020)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "HIV-1 Infection" ], "interventions": [ { "name": "DOR/ISL", "type": "DRUG" }, { "name": "BIC/FTC/TAF", "type": "DRUG" }, { "name": "Placebo to BIC/FTC/TAF", "type": "DRUG" }, { "name": "Placebo to DOR/ISL", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 599, "start_date": "2020-02-28", "completion_date": "2025-01-29", "has_results": true, "last_update_posted_date": "2026-06-03", "last_synced_at": "2026-09-03T08:12:08.737Z", "location_count": 17, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 14 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Ft. Pierce", "state": "Florida" }, { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT04233879" }, { "nct_id": "NCT06630286", "title": "Study to Compare an Oral Weekly Islatravir/Lenacapavir Regimen With Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed People With HIV-1", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "HIV-1-infection" ], "interventions": [ { "name": "ISL/LEN", "type": "DRUG" }, { "name": "B/F/TAF", "type": "DRUG" }, { "name": "PTM B/F/TAF", "type": "DRUG" }, { "name": "PTM ISL/LEN", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 609, "start_date": "2024-10-09", "completion_date": "2030-08", "has_results": false, "last_update_posted_date": "2026-04-30", "last_synced_at": "2026-09-03T08:12:08.737Z", "location_count": 60, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 50 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06630286" }, { "nct_id": "NCT05836688", "title": "A Biobehavioral Intervention to Reduce Adverse Outcomes in Young Adult Testicular Cancer Survivors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Testicular Cancer" ], "interventions": [ { "name": "Goal-Focused Emotion-Regulation Therapy (GET)", "type": "BEHAVIORAL" }, { "name": "Individual Supportive Listening", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "University of California, Irvine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "39 Years", "sex": "MALE", "summary": "18 Years to 39 Years · Male only" }, "enrollment_count": 250, "start_date": "2023-11-01", "completion_date": "2028-07", "has_results": false, "last_update_posted_date": "2025-05-01", "last_synced_at": "2026-09-03T08:12:08.737Z", "location_count": 1, "location_summary": "Irvine, California", "locations": [ { "city": "Irvine", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05836688" } ] }